Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Marvell Technology has its earnings behind it and Wall Street's response is unambiguous: the stock gained 9% on the week to $287.01, and analysts were falling over themselves on Wednesday to lift targets, with at least ten firms publishing fresh numbers in a single session.
The Street's reaction to the October 6 print was broad and bullish. Every firm that updated on Wednesday raised its price target, and the range of revisions tells the story: Jefferies pushed its target to $450, RBC moved to $425, Piper Sandler went to $400. TD Cowen took the more decisive step of upgrading outright, moving from Hold to Buy with a target of $350, up from $245. JP Morgan's Harlan Sur raised to $360 and Wells Fargo to $365, both maintaining Overweight. Morgan Stanley lifted to $300 but held at Equal-Weight, the lone holdout at the cautious end. The consensus rating is a firm buy, with 33 buy recommendations, eight outperforms, and four holds. The mean price target of $338 leaves implied upside of roughly 18% from current levels, though targets issued today imply a considerably wider range. Bulls point to data center sequential growth near 9%, an interconnect business projected to grow more than 50% year-on-year in FY27, and a PEG ratio of 0.38 that remains well below peer averages. Bears flag the dependence on hyperscaler spending and a modest sequential compression in gross margins. The P/E has expanded materially, reaching 45.7x on a trailing basis, up nearly 8 points over the past month, and price-to-book has risen to 11.7x over the same period, a reflection of how aggressively the market has re-rated the growth story.
Positioning is relaxed rather than charged. Short interest has continued the steady unwind described in the pre-earnings note, now down 27% over the past month to 3.1% of the free float, a level too modest to create meaningful friction in either direction. The borrow market remains essentially open: availability is at 9,999%, an effectively unconstrained lending pool, and cost to borrow has edged up 42% on the week to 0.43%, still firmly in low-cost territory. That tick higher in borrow cost is worth watching but is far more likely to reflect routine settlement mechanics after the post-earnings move than any genuine demand for a short position. The ORTEX short score has drifted down to 31.2, its lowest in the recent history shown, consistent with shorts continuing to exit rather than rebuild. Options positioning is modestly more cautious: the put/call ratio of 1.24 is about 1.6 standard deviations above its 20-day mean of 1.21, and at its highest reading in several weeks, though still well inside the 52-week peak of 1.39. That mild elevation in the PCR likely captures some hedging activity from existing long holders after a 28% one-month gain rather than fresh bearish conviction.
Institutional ownership underscores the stock's growing profile among large allocators. BlackRock held 85.6 million shares as of September 30, representing 9.8% of outstanding shares, with a net addition of 21.8 million shares in the most recent reporting period. State Street added 18.5 million shares to reach 4.8% in the same window, and T. Rowe Price added 12.1 million shares to reach 1.6%. Vanguard Capital Management also reported a stake increase, moving from 5.3% to 7.6%. On the other side, the Vanguard Group's 13G/A filed in March showed a reduction from 9.2% to zero, a significant exit that predates the current rally. The activist register carries no 13D filers; all large holders are passive. Recent insider activity is routine and pre-planned: CEO Matthew Murphy sold 7,500 shares on September 15 under a 10b5-1 plan, as did President and COO Chris Koopmans on October 1, a further 10,000 shares also under a standing plan. These are scheduled disposals rather than discretionary conviction trades.
The earnings history adds one data point that long holders will have noted. The August 27 print produced a one-day decline of 11.6% and a five-day fall of 14.8%. The stock's reaction on October 6 is not yet reported with a one-day move figure in the dataset, but the weekly gain of 9% suggests the market's response to this quarter was materially better. The next print is scheduled for December 3, 57 days away, which gives the newly raised targets time to either anchor or be tested by fresh guidance.
What to watch over the coming weeks is whether the multiple can hold near these levels as the revenue growth rate becomes the primary justification: with the P/E above 45x and analysts spread across a target range from $300 to $450, the gap between the most and least optimistic Street views is itself the most instructive measure of how much uncertainty remains embedded in the data center growth story.
See the live data behind this article on ORTEX.
Open MRVL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
